How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,179 results for

Hepatotoxic Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Dr. Stahl's Medical Writer Fights Back

Dr. Stahl's Medical Writer Fights Back The Carlat Psychiatry Blog: Dr. Stahl's Medical Writer Fights Back | Keeping Psychiatry Honest Since 2007 Wednesday, August 31, 2011 Dr. Stahl's Medical Writer Fights Back Dr. Stahl's controversial on the evils of pharmascolds and antipsychiatry has attracted nearly as many comments as all of his prior blog posts combined. Most of the comments have been highly critical of his viewpoint. But we have yet to hear a response from the man himself. However, his (...) medical writer, Debbi Ann Morrissette, PhD, has just mounted a spirited rebuttal to my comment. At the end of her comments, she writes that she will try to post it as a comment on my blog, but she fears that it will not show up because, in her words (and her capitalization): "MOST COMMENTS THAT ARE NOT "ANTI-PHARMA" ARE CENSORED THERE AND NOT POSTED WHEN SUBMITTED." Well, I can assure her that I very rarely reject any comments on my blog--unless they use extreme profanity or appear to be libelous

2011 The Carlat Psychiatry Blog

102. [Diclofenac sodium in osteoarthritis. Is there risk of hepatotoxicity? A systematic review]. (PubMed)

, Cochrane Database, databases of medical publishers and search engines. Total amount of patients in all trials was 1121. 583 patients took diclofenac and 538 ones took placebo. Meta-analysis was performed in StatsDirect software. We estimated 95% confidence interval, Q and 12 criteria, Mantel-Haenszel and DerSimonian-Laird statistics and relative risk of adverse reactions. Relative risk of hepatitis in diclofenac group did not differ from placebo. Hereby the fact of diclofenac hepatotoxicity needs more (...) [Diclofenac sodium in osteoarthritis. Is there risk of hepatotoxicity? A systematic review]. Diclofenac sodium is one of the most prescribed NSAIDs in the world which is frequently used in therapy of musculosceletal diseases. Therefore it is important to justify clinical and literary data about diclofenac hepatotoxicity. We searched for diclofenac versus placebo investigations performed in patients with osteoarthrosis. A method of the search included international databases such as EMBASE

2010 Ėksperimental'nai͡a i klinicheskai͡a gastroėnterologii͡a = Experimental & clinical gastroenterology

103. An Evaluation of Hepatotoxicity and Nephrotoxicity of Liposomal Amphotericin B (L-AMB) (PubMed)

An Evaluation of Hepatotoxicity and Nephrotoxicity of Liposomal Amphotericin B (L-AMB) Hepatic and renal functions are important considerations when selecting antifungal therapy. This investigation of liposomal amphotericin B (L-AMB) was conducted to determine the incidence and factors associated with the development of hepatotoxicity and nephrotoxicity. A retrospective chart review was conducted of 100 consecutive patients receiving L-AMB at doses of 1, 3, and 5 mg/kg. Hepatotoxicity (...) (16/75) developed hepatotoxicity based upon the predefined criteria. There were no additive correlates for this adverse effect. Overall, 56% (42/75) of patients developed nephrotoxicity. Seventy-four percent (31/42) were exposed to IV contrast, and 90% (38/42) were receiving nephrotoxins concurrently. Age, cumulative dose, concomitant nephrotoxins, and IV contrast exposure were associated with increased nephrotoxicity (p<0.001). The development of hepatotoxicity was observed; however

Full Text available with Trip Pro

2010 Journal of Medical Toxicology

104. Hydroxycut® (herbal weight loss supplement) Induced Hepatotoxicity: A Case Report and Review of Literature (PubMed)

Hydroxycut® (herbal weight loss supplement) Induced Hepatotoxicity: A Case Report and Review of Literature Use of supplement and alternative drugs continues to thrive and is becoming an increasing cause of concern since many of these substances may have unexpected or unexplained medical consequences. We present below the first reported case of hepatotoxicity from Hydroxycut(®) in Hawaii.Hawaii Medical Journal Copyright 2010.

Full Text available with Trip Pro

2010 Hawaii Medical Journal

105. Dissimilar Hepatotoxicity Profiles of Propylthiouracil and Methimazole in Children. (PubMed)

Dissimilar Hepatotoxicity Profiles of Propylthiouracil and Methimazole in Children. The antithyroid drugs propylthiouracil and methimazole were introduced for clinical use about 60 yr ago and are estimated to be used in more than 6000 children and adolescents per year in the United States. Over the years that these medications have been used, reports of adverse events involving hepatotoxicity have appeared. To date, there has not been a systematic and comparative evaluation of the adverse (...) events associated with antithyroid drug use.Our objective was to assess safety and hepatotoxicity profiles of propylthiouracil and methimazole by age in the U.S. Food and Drug Administration's Adverse Event Reporting System (AERS).We used the multi-item gamma-Poisson shrinker (MGPS) data mining algorithm to analyze more than 40 yr of safety data in AERS. MGPS uses a Bayesian model to calculate adjusted observed to expected ratios [empiric Bayes geometric mean (EBGM) values] for every drug-adverse

Full Text available with Trip Pro

2010 Journal of Clinical Endocrinology and Metabolism

106. Hepatotoxicity Due to Hydroxycut: A Case Series. (PubMed)

Hepatotoxicity Due to Hydroxycut: A Case Series. Muscletech Hydroxycut (Iovate Health Sciences Research, Oakville, Ontario, Canada) was a popular weight-loss supplement that was recalled by the manufacturer in May 2009 on the basis of reports of hepatotoxicity associated with this supplement. We sought to characterize the clinical presentation of Hydroxycut-associated liver injury and to adjudicate these cases for causal association with Hydroxycut.We assessed the causality and grading (...) of severity of liver injury using methodology developed by the Drug-Induced Liver Injury Network (DILIN) study.Eight patients who developed liver injury after taking Hydroxycut treated at different medical centers were identified. All were hospitalized, and three of eight patients required liver transplantation. Nine other cases with adequate clinical information were obtained from the FDA MedWatch database, including one fatal case of acute liver failure. Usual symptoms were jaundice, fatigue, nausea

Full Text available with Trip Pro

2010 American Journal of Gastroenterology

107. Canadian guideline for Parkinson disease

sleep behaviour disorder can pre-date the diagnosis of Parkinson disease. PALLIATIVE CARE n The palliative care needs of people with Parkinson disease should be considered throughout all phases of the disease. n If the patient asks, the option of medical assistance in dying should be discussed. TREATMENT n Levodopa is the most eective medication and may be used early. n A regular exercise regimen begun early has proven benet. n Patients with possible diagnosis of Parkinson disease may benet from (...) the diagnosis of Parkinson disease. PALLIATIVE CARE n The palliative care needs of people with Parkinson disease should be considered throughout all phases of the disease. n If the patient asks, the option of medical assistance in dying should be discussed. TREATMENT n Levodopa is the most eective medication and may be used early. n A regular exercise regimen begun early has proven benet. n Patients with possible diagnosis of Parkinson disease may benet from a trial of dopamine replacement therapy to help

2019 CPG Infobase

108. Interventions for morphea. (PubMed)

to July 2018: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, and five trial registers. We checked the reference lists of included studies for further references to relevant randomised controlled trials.Randomised controlled trials of topical, intralesional, or systemic treatments (isolated or combined) in anyone who has been clinically diagnosed by a medical practitioner with any form of morphea. Eligible controls were placebo, no intervention, any other treatment (...) , or different doses or duration of a treatment.We used standard methodological procedures expected by Cochrane. The primary outcomes were global improvement of disease activity or damage assessed by a medical practitioner or by participants, and adverse effects. Secondary outcomes were improvement of disease activity and improvement of disease damage. We used GRADE to assess the quality of the evidence for each outcome.We included 14 trials, with a total of 429 randomised participants, aged between 3 and 76

2019 Cochrane

109. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA

(CRC) provides specifically for children’s access to health services and obliges states to ‘ensure appropriate prenatal and postnatal healthcare for mothers’ (49). The reference to adequate access to healthcare for mothers is motivated by the strong impact that maternal morbidity and mortality may have on children’s health. The CRC requires that Member States ensure the provision of necessary medical assistance and healthcare with an emphasis on provision of primary healthcare (50). Article 12 [2 (...) ] of the UN Convention on the Elimination of all Forms of Discrimination against Women provides similar healthcare rights to pregnant women (51). At the EU level, the Charter of Fundamental Rights of the European Union (the Charter) includes the right to healthcare under Article 35, which states that ‘everyone has the right of access to preventive healthcare and the right to benefit from medical treatment under the conditions established by national laws and practices’ (52). The Charter’s application

2019 European Centre for Disease Prevention and Control - Public Health Guidance

110. Programmatic management of latent tuberculosis infection in the European Union

opinions; the evidence collection, appraisal and synthesis; the expert consultation and the first draft of this guidance were produced by Marije Vonk Noordegraaf-Schouten, Femke van Kessel and Anouk Oordt, members of a consortium of Pallas Health Research and Consultancy (Rotterdam) and Erasmus University Medical Center (framework contracts no ECDC/2013/005 and ECDC/2014/032). Invaluable input was received from ad hoc scientific panel chairs Gerard de Vries (the Netherlands) and Dominik Zenner (United (...) ). People with drug use disorders Persons who use narcotic drugs and psychotropic substances without medical supervision, for non- medical purposes [11]. This definition includes people who inject drugs. Other terms such as drug users, injecting drug users or problematic drug users are used only if the cited reference has used these terms. Programmatic management of LTBI Management of latent tuberculosis infection requires input from different components or units responsible for tuberculosis prevention

2019 European Centre for Disease Prevention and Control - Public Health Guidance

111. A Case Management Tool for TB Prevention, Care and Control in the UK

assessment (Form: 3) 41 – DOT chart/log (Form: 4) 43 2. Sample DOT contract 44 3. Sample social/network questionnaire 46 4. Standard case management – flow chart 47 5. Tips for giving medication to children 48 6. Home isolation policy 49 7. Sample cohort review action log 52 8. Cohort review incident reporting form 53 9. Outreach and safe practice 54 10. Methadone and anti-tuberculous treatment containing rifamycins 55 11. Managing treatment interruptions 58 12. Drug therapy – adverse effects requiring (...) (ECM) commences from suspicion of disease and may include directly observed treatment (DOT), monitoring drug levels, hepatotoxicity, and/or a package of supportive care tailored to a patient’s needs which should be available in both high and low incidence areas. The service should include all socially and/or clinically complex patients, including those who are vulnerable (older people), those in denial of diagnosis, and those where there is interruption to TB treatment. ECM must be available to TB

2019 Royal College of Nursing

112. Management of Dyslipidaemias

and are regularly updated. The ESC carries out a number of registries which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on data collected during routine clinical practice. The guidelines are developed together with derivative educational material addressing the cultural and professional needs for cardiologists and allied professionals (...) . Collecting high-quality observational data, at appropriate time interval following the release of ESC Guidelines, will help evaluate the level of implementation of the Guidelines, checking in priority the key end points defined with the ESC Guidelines and Education Committees and Task Force members in charge. The Members of this Task Force were selected by the ESC and EAS, including representation from relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care

Full Text available with Trip Pro

2019 European Society of Cardiology

113. Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Melanoma

is expected to use independent medical judgment in the context of individual clinical circumstances or to seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representations or guarantees of any kind whatsoever regarding the report content or its use or application and disclaims any responsibility for its use or application in any way. Guideline 8-1 version 5 Page iii Table of Contents Section 1: Recommendations 1 Section 2: Guideline – Recommendations and Key Evidence 5 (...) cutaneous or mucosal melanoma with a high risk of recurrence. TARGET POPULATION Adult patients with cutaneous or mucosal melanoma with high risk of recurrence who are rendered disease-free following resection (including resection of all locoregional or distant metastases, if present). Patients with unresected primary disease or metastases fall outside the scope of this document. INTENDED USERS Medical oncologists, surgical oncologists, and other health care providers involved in the management

2019 Cancer Care Ontario

114. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus

. S.O. Keeling, 8-129 Clinical Sciences Building, University of Alberta, Edmonton, Alberta T6G 2G3, Canada. E-mail: Stephanie.keeling@ualberta.ca Full Release Article. For details see Reprints and Permissions at jrheum.org Accepted for publication July 13, 2018. of Rheumatology The Journal on March 26, 2019 - Published by www.jrheum.org Downloaded from for the assessment and monitoring of SLE. The International Committee of Medical Journal Editors conflict of interest form was completed and reviewed (...) -risk medications, or who have hypogonadism or premature menopause. This recommen- dation does not apply to the pediatric SLE population, where osteoporosis is defined by fractures and not BMD (www.iscd.org/official-positions/2013-iscd-official- positions-pediatric). Justification: Current guidelines in Canada recommend assessing risk of osteoporosis in individuals over age 50 every 1 to 3 years 38 . There is no evidence comparing outcomes related to osteoporosis in patients with SLE who had or did

2018 CPG Infobase

115. Paracetamol overdose

. The definition of hepatotoxicity after paracetamol overdose is a serum AST concentration at least 1000 IU/L. Paracetamol is known as acetaminophen in some countries. History and exam attempted self-harm repeated non-prescription analgesic use for pain relief asymptomatic presentation nausea, vomiting, or abdominal pain right upper quadrant pain and tenderness jaundice confusion, decreased consciousness level, and/or asterixis history of self-harm history of frequent or repeated use of medications for pain (...) Paracetamol overdose Paracetamol overdose - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Paracetamol overdose Last reviewed: February 2019 Last updated: September 2018 Summary Overdose may occur after an acute single ingestion of a large amount of paracetamol or paracetamol-containing medication, or repeated ingestion of an amount exceeding recommended dosage. Patients are often asymptomatic or have only mild

2018 BMJ Best Practice

116. Paracetamol overdose

. The definition of hepatotoxicity after paracetamol overdose is a serum AST concentration at least 1000 IU/L. Paracetamol is known as acetaminophen in some countries. History and exam attempted self-harm repeated non-prescription analgesic use for pain relief asymptomatic presentation nausea, vomiting, or abdominal pain right upper quadrant pain and tenderness jaundice confusion, decreased consciousness level, and/or asterixis history of self-harm history of frequent or repeated use of medications for pain (...) Paracetamol overdose Paracetamol overdose - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Paracetamol overdose Last reviewed: February 2019 Last updated: September 2018 Summary Overdose may occur after an acute single ingestion of a large amount of paracetamol or paracetamol-containing medication, or repeated ingestion of an amount exceeding recommended dosage. Patients are often asymptomatic or have only mild

2018 BMJ Best Practice

117. Acute liver failure

://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381946/ http://www.ncbi.nlm.nih.gov/pubmed/18318440?tool=bestpractice.com History and exam presence of risk factors hepatotoxic medication jaundice signs of hepatic encephalopathy absence of hx of chronic liver disease abdominal pain nausea vomiting malaise signs of cerebral oedema abdominal or right upper quadrant tenderness hepatomegaly absence of splenomegaly absence of spider angiomata absence of palmar erythema absence of ascites depression or suicidal ideation exposure (...) to hepatotoxins illicit drug abuse and high-risk behaviours chronic alcohol abuse poor nutritional status female sex age >40 years pregnancy chronic hepatitis B chronic pain and narcotic use complementary and alternative medicine hepatotoxicity paracetamol and antidepressant therapy chronic hepatitis C HIV and hepatitis C co-infection Diagnostic investigations liver function tests prothrombin time/INR basic metabolic panel FBC blood type and screen arterial blood gas arterial blood lactate paracetamol level

2018 BMJ Best Practice

118. Statins for the primary prevention of cardiovascular events

the risks, benefits, alternatives, and uncertainties; • has weighed his or her values regarding the potential benefits and harms associated with the service; • has engaged in decision making at a level at which he or she desires and feels comfortable. Whether or not the overall benefit-harm balance justifies the use of a medication for an individual patient cannot be determined by a guidelines committee, a health care system, or even the attending physician. Instead, it is the individual patient who has (...) HISTORICAL AND CURRENT STATIN USE IN BELGIUM 3.1 Introduction Statins (also known as HMG-CoA reductase inhibitors) are a class of lipid- lowering medications. Statins proved to reduce the relative risk for cardiovascular disease (CVD), CVD events and mortality similarly in all individuals, but the absolute risk reduction is much greater in those who are at high risk of CVD events. Statins are used both in the primary and secondary prevention of CVD. Clinical practice guidelines generally recommend

2019 Belgian Health Care Knowledge Centre

119. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU

Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL/Certifications Exam Prep Research Research Funding AUA Funding Research Education & Events Online Research Education Courses Research Resources Biorepositories and Other Resources Research Publications Research Career Opportunities Advocacy Scholar & Fellowship Programs Comment Letters & Resources International International Opportunities Annual Meeting Membership Collaborations Academic Exchanges Giving Back (...) agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. Expert Opinion refers to a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there is no evidence. Table 2: AUA Nomenclature Linking Statement Type to Level of Certainty, Magnitude of Benefit or Risk/Burden, and Body of Evidence Strength Evidence Strength A (High Certainty) Evidence Strength B

2019 Canadian Urological Association

120. Tuberculosis

Adherence, treatment completion and follow-up 56 1.8 Service organisation 62 T erms used in this guideline 77 Context 87 More information 88 Recommendations for research 89 1 Universal compared with risk-based approach to using rapid diagnostic tests 89 2 Diagnosis in children 89 3 Treating isoniazid-resistant TB 90 4 Impact of infection control measures on quality of life 90 5 Treatment interruptions caused by adverse events (specifically hepatotoxicity) 90 Update information 92 Recommendations from (...) the potential interaction of TB medication with other drugs, for example, oral contraceptives and opioids (especially methadone) and HIV treatment TB/HIV co-infection how to address the myths about TB infection and treatment (for example, to counter the belief that TB is hereditary) how to address the stigma associated with TB the risk of migrants from high-incidence countries developing active TB – even if they have already screened negative for it contact tracing. [2012, amended 2016] [2012, amended 2016

2016 National Institute for Health and Clinical Excellence - Clinical Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>